文献速递妇科

评估高强度聚焦超声治疗直肠子宫内膜异位症的安全性:法国前瞻性多中心研究纳入60例患者的结果

Evaluating the safety of high-intensity focused ultrasound treatment for rectal endometriosis: results from a French prospective multicentre study including 60 patients.
PubMed 文献 · Hum Reprod · 2024-01-01

本研究为2020至2022年法国前瞻性多中心队列研究,纳入60例有症状的直肠子宫内膜异位症患者,在药物治疗失败后以高强度聚焦超声(HIFU)替代手术,HIFU强度较前增加30%。结果显示无Clavien-Dindo III级或以上并发症,尤其无直肠阴道瘘;6个月随访中妇科、消化及一般症状和健康状况均显著改善,结节体积缩小28%(P < 0.001)。

要点

  • HIFU强度增加30%治疗直肠子宫内膜异位症,无Clavien-Dindo III级或以上并发症,尤其无直肠阴道瘘。
  • 6个月随访中妇科、消化及一般症状与健康状况均显著改善,结节体积缩小28%(P < 0.001)。
  • 作者认为对选定患者,药物治疗失败后HIFU可能是手术之外的有价值替代选择。

核心结论

  • 本研究显示HIFU强度增加30%治疗直肠子宫内膜异位症是安全的,总体无Clavien-Dindo III级并发症,尤其无直肠阴道瘘。
  • HIFU治疗直肠子宫内膜异位症可改善症状且发病率低;作者认为对选定患者,药物治疗失败后它可能是手术之外的有价值替代选择。

研究设计与样本

  • 前瞻性多中心队列研究,于2020年至2022年开展,纳入60例有症状的直肠子宫内膜异位症患者。
  • 患者在药物治疗失败后接受HIFU治疗作为手术的替代选择。
  • 主要目的为评估安全性,分析6个月随访期间所有不良事件,并按美国国家癌症研究所不良事件通用术语标准(CTCAE)和Clavien-Dindo分类分级。

主要发现

  • 30%的患者在脊髓麻醉下完成操作,中位治疗时长32分钟,55例患者在术后第1天离院。
  • 术后第1天MRI未发现任何早发性术后并发症。
  • 按Clavien-Dindo分类,I级事件占56.7%,II级事件占3.4%,无III级或以上事件。
  • 在1、3、6个月时,所有妇科、消化及一般症状以及健康状况均显著改善。
  • 结节演变亦显著(P < 0.001),体积缩小28%。

关键数值与推荐

  • 主要安全性结果:Clavien-Dindo I级事件56.7%,II级事件3.4%,无III级或以上事件。
  • 结节体积在6个月时缩小28%(P < 0.001)。
  • 30%的患者在脊髓麻醉下接受操作,中位治疗时长32分钟。

临床怎么用

  • 作者认为,对选定患者,药物治疗失败后HIFU可能是手术之外的有价值替代选择。
  • 原文未据此给出其他临床推荐。

局限性

  • 主要目的为安全性而非有效性。
  • 研究未随机化,且无对照组。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is increasing the intensity of high-intensity focused ultrasound (HIFU) by 30% in the treatment of rectal endometriosis a safe procedure? SUMMARY ANSWER: This study demonstrates the safety of a 30% increase in the intensity of HIFU in the treatment of rectal endometriosis, with no Clavien-Dindo Grade III complications overall, and namely no rectovaginal fistulae. WHAT IS KNOWN ALREADY: A feasibility study including 20 patients with rectal endometriosis demonstrated, with no severe complications, a significant improvement in digestive disorders, dysmenorrhoea, dyspareunia, and health status, although the volume of the endometriosis nodule did not appear to be reduced. STUDY DESIGN, SIZE, DURATION: A prospective multicentre cohort study was conducted between 2020 and 2022 with 60 patients with symptomatic rectal endometriosis. Following the failure of medical treatment, HIFU treatment was offered as an alternative to surgery. PARTICIPANTS/MATERIALS, SETTING, METHODS: As the main objective of this study was to examine safety, all adverse events observed during the 6 months of follow-up were analysed and graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE) and Clavien-Dindo classifications. Secondary objectives included evaluating the evolution of symptoms using validated questionnaires: gynaecological and digestive pain symptoms with a visual analogue scale, health status with the Medical Outcomes Study 36-item Short Form (SF-36) questionnaire, average post-operative daily pain level, and analgesic medication required in the 10 days following treatment. MRI was also performed at Day 1 to detect early complications. Finally, we performed a blinded MRI review of the evolution of the nodule at 6 months post-treatment. MAIN RESULTS AND THE ROLE OF CHANCE: The procedure was performed under spinal anaesthesia for 30% of the patients. The median duration of treatment was 32 min. Fifty-five patients left the hospital on Day 1. MRI scans performed on Day 1 did not highlight any early-onset post-operative complication. Using the Clavien-Dindo classification, we listed 56.7% Grade I events, 3.4% Grade II events, and no events Grade III or higher. At 1, 3, and 6 months, all gynaecologic, digestive and general symptoms, as well as health status, had significantly improved. The evolution of the nodule was also significant (P < 0.001) with a 28% decrease in volume. LIMITATIONS, REASONS FOR CAUTION: The main objective was safety and not effectiveness. The study was not randomized and there was no control group. WIDER IMPLICATIONS OF THE FINDINGS: HIFU treatment for rectal endometriosis results in an improvement of symptoms with low morbidity; as such, for selected patients, it could be a valuable alternative to surgical approaches following the failure of medical treatment. STUDY FUNDING/COMPETING INTEREST(S): The study was funded by the company EDAP TMS. Professors Dubernard and Rousset are consultants for EDAP TMS. Dubernard received travel support from EDAP-TMS. Dr F. Chavrier received industrial grants from EDAP-TMS. He has developed a device for generating focused ultrasonic waves with reduced treatment time. This device has been patented by EDAP-TMS. Dr Lafon received industrial grants from EDAP-TMS; he declares that EDAP-TMS provided funding directly to INSERM to support a young researcher chair in therapeutic ultrasound, which is unrelated to the current study. TRIAL REGISTRATION NUMBER: ClinicalTrials.gov identifier NCT04494568.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Dubernard G, Maissiat E, Legendre G, et al. Evaluating the safety of high-intensity focused ultrasound treatment for rectal endometriosis: results from a French prospective multicentre study including 60 patients. Hum Reprod. 2024. PMID: 38914481. doi:10.1093/humrep/deae127

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。